Lite Strategy (LITS) Income from Continuing Operations (2010 - 2026)
Lite Strategy (LITS) posted quarterly Income from Continuing Operations of 22394000.0 for Q1 2026, down 617.76% year-over-year from 4325199.95 in Q1 2025, and up 26.96% quarter-over-quarter from 30658000.0 in Q4 2025.
Lite Strategy (LITS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lite Strategy's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 22394000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 617.76% year-over-year to 22394000.0; the TTM figure through Mar 2026 stood at 133082000.0 (down 193.99% YoY), while the FY2025 annual figure was 90129000.0, down 2242.36% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 22394000.0, up from 30658000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 52964000.0 in Q3 2023, with the low at 76388000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 11644000.0 (2023), against an average of 15184117.65.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 247.88% in 2023, then slumped 760.94% in 2025.
- Lite Strategy's Income from Continuing Operations stood at 5631000.0 in 2022, then sank by 306.78% to 11644000.0 in 2023, then soared by 69.42% to 3561000.0 in 2024, then plunged by 760.94% to 30658000.0 in 2025, then grew by 26.96% to 22394000.0 in 2026.
- Business Quant data shows LITS's Income from Continuing Operations at 22394000.0 in Q1 2026, 30658000.0 in Q4 2025, and 3642000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -21.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.39 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Sep 30, 2025 | -3.64 Mn |
| Jun 30, 2025 | -76.39 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Dec 31, 2024 | -3.56 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -30.23 Mn |
| Mar 31, 2024 | -9.71 Mn |
| Dec 31, 2023 | -11.64 Mn |
| Sep 30, 2023 | 52.96 Mn |
| Jun 30, 2023 | -10.58 Mn |
| Mar 31, 2023 | -32.38 Mn |
| Dec 31, 2022 | 5.63 Mn |
| Sep 30, 2022 | -35.82 Mn |
| Jun 30, 2022 | -16.37 Mn |
| Mar 31, 2022 | -21.88 Mn |
| Dec 31, 2021 | -21.05 Mn |
| Sep 30, 2021 | -24.23 Mn |
| Jun 30, 2021 | -69.17 Mn |